United States $140 Billion Pharmaceutical Giant Pfizer Announced $100 Million Equity Investment in Hong Kong-Listed $8.6 Billion China Biopharmaceutical Company 3SBio, $1.25 Billion Upfront Payment for Exclusive Rights to 3SBio Cancer Drug (SSGJ-707) Global ex-China & $150 Million Optional Payment to Develop & Commercialize Cancer Drug (SSGJ-707) in China Mainland, 3SBio Founded in 1993 by Lou Jing & Lou Dan
27th July | Hong Kong
United States pharmaceutical giant Pfizer ($140 billion market value) has announced a $100 million equity investment in Hong Kong-listed China biopharmaceutical company 3SBio ($8.6 billion market value), and $1.25 billion upfront payment for exclusive rights to 3SBio cancer drug (SSGJ-707) Global ex-China & $150 million optional payment to develop & commercialize cancer drug (SSGJ-707) in China Mainland. 3SBio was founded in 1993 by Lou Jing & Lou Dan. 3SBio – 3S Pharmaceutical Group 3S Pharmaceutical Group is a leading bio-pharmaceutical company integrating R&D, production and sales, with a focus on improving the life quality of patients with high-quality medicines to benefit human health. At present, the Group owns more than 80 national invention patents and has launched more than 30 kinds of products into the market, covering several treatment fields, among others, cancer, autoimmune, kidney disease, metabolism and dermatology. The Group owns 4 R&D centers of the National Engineering Research Center of Antibody Medicine and dual platforms for biopharmaceutical and chemical medicine. There are 25 kinds of products under R&D, 16 kinds of them are under R&D as the national first-class new drugs. The Group also owns 6 production bases complying with GMP standards. In the future, 3S Pharmaceutical Group will continue to uphold the concept of “Care for Life, Cherish Life, Create Life” to create a world’s leading bio-pharmaceutical company in China. Pfizer – At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us.
“ United States $140 Billion Pharmaceutical Giant Pfizer Announced $100 Million Equity Investment in Hong Kong-Listed $8.6 Billion China Biopharmaceutical Company 3SBio, $1.25 Billion Upfront Payment for Exclusive Rights to 3SBio Cancer Drug (SSGJ-707) Global ex-China & $150 Million Optional Payment to Develop & Commercialize Cancer Drug (SSGJ-707) in China Mainland, 3SBio Founded in 1993 by Lou Jing & Lou Dan “
![](https://www.caproasia.com/wp-content/uploads/2025/08/Air-Charter-Service-728x90-1.png")
United States $140 Billion Pharmaceutical Giant Pfizer Announced $100 Million Equity Investment in Hong Kong-Listed $8.6 Billion China Biopharmaceutical Company 3SBio, $1.25 Billion Upfront Payment for Exclusive Rights to 3SBio Cancer Drug (SSGJ-707) Global ex-China & $150 Million Optional Payment to Develop & Commercialize Cancer Drug (SSGJ-707) in China Mainland, 3SBio Founded in 1993 by Lou Jing & Lou Dan
Caproasia Users
- Manage $20 million to $30 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2026 Investment Day
- March - Hong Kong
- March - Singapore
- April - Hong Kong
- April - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
